- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07650279
Coherence Breathing Before Cardiopulmonary Exercise Testing
Acute Effects of Coherence Breathing on Cardiopulmonary Exercise Responses in Recreationally Active Adults: A Randomized Crossover Trial
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Slow-paced breathing performed at approximately six breaths per minute has been shown to influence autonomic nervous system activity and heart rate variability. Coherence breathing may improve physiological regulation by enhancing cardiorespiratory synchronization and vagal modulation. However, little is known about whether a brief bout of coherence breathing performed immediately before exercise can influence cardiopulmonary exercise performance. The purpose of this study is to investigate the acute effects of pre-exercise coherence breathing on cardiopulmonary exercise performance and autonomic responses in recreationally active adults. This study will utilize a randomized, counterbalanced crossover design. Recreationally active adults aged 19 to 45 years will complete two experimental conditions in random order separated by a minimum of 48 hours (maximum of 7 days). In one condition, participants will perform 5 minutes of guided coherence breathing using a visual breathing pacer at approximately 6 breaths per minute while seated. In the comparison condition, participants will sit quietly for 5 minutes with spontaneous breathing. Following each condition, participants will complete a standardized treadmill warm-up and a maximal cardiopulmonary exercise test (CPET). Heart rate variability will be assessed during baseline seated rest and during the breathing intervention. Cardiopulmonary variables collected during CPET will include oxygen consumption, heart rate, respiratory responses, and ratings of perceived exertion. Recovery responses over 5 minutes seated include heart rate and blood pressure will also be assessed following exercise.
Findings from this study may improve our understanding of breathing strategies for athletic performance. Specifically, whether slow paced breathing through coherence breathing can serve as a practical autonomic priming strategy before maximal exercise. Moreover, insights from this study may provide insight into the acute interaction between breathing regulation, autonomic function, and exercise responses.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tamara Rial-Faigenbaum, PhD
- Numéro de téléphone: 2159878984
- E-mail: trialfai@monmouth.edu
Sauvegarde des contacts de l'étude
- Nom: Jaime Pigman, PhD
- Numéro de téléphone: 732-749-0160
- E-mail: jpigman@monmouth.edu
Lieux d'étude
-
-
New Jersey
-
West Long Branch, New Jersey, États-Unis, 07764
- Monmouth University Graduate Center, Human Performance Lab, Room 222
-
Contact:
- Tamara Rial-Faigenbaum, PhD
- Numéro de téléphone: 2159878984
- E-mail: trialfai@monmouth.edu
-
Contact:
- Jaime Pigman, PhD
- Numéro de téléphone: 732-749-0160
- E-mail: jpigman@monmouth.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Inclusion Criteria:
- Adults aged 19 to 45 years.
- Any biological sex.
- Recreationally active, defined as accumulating at least 3 hours per week of moderate-to-vigorous physical activity.
- Able to perform maximal cardiopulmonary exercise testing on a treadmill.
- Able to provide informed consent.
- Cleared for moderate-to-vigorous physical activity based on the PAR-Q+ (or PAR-Q 2023).
Exclusion Criteria:
- Accumulate less than 3 hours per week of moderate-to-vigorous physical activity.
- Presence of a health condition that contraindicates maximal exercise testing, including:
Cardiovascular disease. Pulmonary disease. Metabolic disorders. Neuromuscular disorders. Orthopedic limitations that impair exercise performance.
- Acute illness that would interfere with participation or exercise testing.
- Inability or unwillingness to complete study procedures.
- Inability or unwillingness to provide informed consent.
- Not cleared for moderate-to-vigorous physical activity based on the PAR-Q+ (or PAR-Q+ 2023).
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation croisée
- Masquage: Seul
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Coherence Breathing
Participants complete 5 minutes of guided coherence breathing
|
Participants complete 5 minutes of guided coherence breathing which consists or around 6 breathing cycles (5 seconds inhale and 5 seconds exhale)
Autres noms:
|
|
Comparateur actif: Spontaneous Breathing
Participants sit quietly for 5 minutes with spontaneous breathing
|
Participants sit quietly for 5 minutes with their regular spontaneous breathing
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Peak Oxygen consumption
Délai: during each maximal exercise test immediately after the breathing condition
|
Peak oxygen consumption measured during the maximal cardiopulmonary exercise test (CPET) using a portable metabolic analyzer (Vo2 Master)
|
during each maximal exercise test immediately after the breathing condition
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
rating of perceived exertion (RPE)
Délai: measured at baseline, during the exercise test and after recovery
|
using the RPE borg scale (from 1-10)
|
measured at baseline, during the exercise test and after recovery
|
|
Heart Rate Recovery
Délai: difference between peak HR during CPET and HR at minute 1, minute 2 and minute 5 of recovery.
|
Heart Rate (bpm) immediately after completing the CPET over a period of 5 minutes
|
difference between peak HR during CPET and HR at minute 1, minute 2 and minute 5 of recovery.
|
|
Time to completion of maximal exercise test
Délai: during the exercise test
|
total duration of the exercise test since test starts to voluntary termination
|
during the exercise test
|
|
Peak Heart Rate
Délai: measured during the maximal exercise test
|
maximal heart rate achieved during the maximal exercise test
|
measured during the maximal exercise test
|
Collaborateurs et enquêteurs
Publications et liens utiles
Publications générales
- Laborde S, Allen MS, Borges U, Dosseville F, Hosang TJ, Iskra M, Mosley E, Salvotti C, Spolverato L, Zammit N, Javelle F. Effects of voluntary slow breathing on heart rate and heart rate variability: A systematic review and a meta-analysis. Neurosci Biobehav Rev. 2022 Jul;138:104711. doi: 10.1016/j.neubiorev.2022.104711. Epub 2022 May 24.
- Sevoz-Couche C, Laborde S. Heart rate variability and slow-paced breathing:when coherence meets resonance. Neurosci Biobehav Rev. 2022 Apr;135:104576. doi: 10.1016/j.neubiorev.2022.104576. Epub 2022 Feb 12.
- Trinkunas E, Kairiukstiene Z, Trinkunaite M, Poderiene K, Brazdzionyte R, Poderys J. Post-Exercise Controlled Breathing Enhances Cardiovascular Recovery and Autonomic Balance: A Randomised Crossover Study. Medicina (Kaunas). 2026 Feb 3;62(2):318. doi: 10.3390/medicina62020318.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- SP2645
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .